In relation, it has been demonstrated that the combination of NF-κB targeted siRNA and MTX in a hybrid nanocarrier could effectively treat the RA in a preclinical model avoiding the adverse effects of MTX and opening a novel therapeutic approach in the treatment of RA [148]. This evidence concerns the gene NFKB1 and rheumatoid arthritis.